Quidel expects to launch at least four new products over the next year and commented on its overall COVID-19 strategy, as well as R&D plans, M&A possibilities, and other updates.
The reissued EUA is for the qualitative detection of nucleic acid from SARS-CoV-2 in human oropharyngeal swab, nasopharyngeal swab, and anterior nasal swab specimens.
The company said that at a time of unparalleled growth, it is building three new manufacturing lines and expanding resources for future assay development.
